Global Down Syndrome

Issue 4 of 4 2017

Issue link: https://viewer.e-digitaledition.com/i/889419

Contents of this Issue

Navigation

Page 8 of 31

BIOTECHNOLOGY LEADER BIOGEN, THE GLOBAL DOWN SYNDROME FOUNDATION, AND THE UNIVERSITY OF COLORADO SCHOOL OF MEDICINE HAVE JOINTLY CONTRIBUTED $2.5 MILLION IN A GROUNDBREAKING DOWN SYNDROME RESEARCH PROJECT. A Transformative Commitment to Down Syndrome Research THESE THREE ORGANIZATIONS have joined forces to support the Crnic Institute Human Trisome Project™ (Crnic Institute HTP™), an ambitious Down syndrome research program established by the Linda Crnic Institute for Down Syndrome at the University of Colorado School of Medicine at the Anschutz Medical Campus. AN 'UNPRECEDENTED' UNDERSTANDING OF DOWN SYNDROME The Crnic Institute HTP™ is a longitudinal, cross-sectional study that will recruit 1,000 individuals with Down syndrome — also known as trisomy 21 — and 500 typical individuals. Scientists and clinicians will sequence and study several layers of genomic information (all de-identified) from a single sample of blood. Saliva, stool, and other samples are also being collected. The Crnic Institute HTP™ has already begun to significantly increase the speed of Down syndrome research. Nearly 300 participants enrolled during the first few months. "People with Down syndrome have a different disease spectrum compared with typical individuals," explained Joaquín Espinosa, Ph.D., Executive Director of the Crnic Institute and the principal investigator of the Crnic Institute HTP™. "The study will allow us to redefine Down syndrome from the least scientifically understood condition to one of the most understood. In addition, it will provide unprecedented understanding of Alzheimer's disease, autoimmune conditions, cancers, and other medical conditions that people with Down syndrome are either predisposed to or protected from, eventually enabling the development of new diagnostic and therapeutic tools." FINDING AND FUNDING CURES Biogen, a pioneer in biotechnology, is dedicated to the discovery, development, and worldwide delivery of innovative therapies for people living with serious neurological and neurodegenerative diseases. One of several key focuses for Biogen is developing a drug to cure Alzheimer's disease, to which most people with Down syndrome are predisposed. Almost every person with Down syndrome will accumulate plaques and tangles in the brain associated with Alzheimer's disease, although estimates suggest 30 percent or more do not develop the dementia or symptoms associated with the condition. Understanding why people with Down syndrome are predisposed to this common form of dementia, while others are protected, may hold the key to a therapy or cure. An estimated 5.4 million Americans have Alzheimer's disease today, and that number is expected to grow to roughly 14 million by 2050. "Our son is 38 years old, and we are concerned that he may get Alzheimer's disease," said Penni Dorwart, whose son enrolled in the Crnic Institute HTP™. "We also know that if we have high-quality research, there is the potential to significantly improve not only his life but also the lives of millions of others with Down syndrome who have many other medical issues that prevent good quality of life." "Down syndrome is one of the genetic conditions least-funded by our federal government, so we must raise our own funds even for great research efforts like that of the Crnic Institute HTP™," said Michelle Sie Whitten, President and CEO of Global. "We hope this initial contribution will attract other biopharmaceutical organizations and philanthropists so we can reach our targeted $35 million over the next five years." To learn more or sign up to participate, visit globaldownsyndrome.org/human-trisome-project. GLOBALDOWNSYNDROME.ORG 9

Articles in this issue

Links on this page

Archives of this issue

view archives of Global Down Syndrome - Issue 4 of 4 2017